Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-05-02
2006-05-02
Ketter, James (Department: 1636)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C530S324000, C435S069100
Reexamination Certificate
active
07037504
ABSTRACT:
Forms of epidermal growth factor that are resistant to proteolysis, and gene sequences encoding these forms and having codons optimized for usage by an industrial production organism, are provided.
REFERENCES:
patent: 3917824 (1975-11-01), Camble et al.
patent: 4686283 (1987-08-01), Nestor, Jr. et al.
patent: 4760023 (1988-07-01), Miyoshi et al.
patent: 5102789 (1992-04-01), Siegel et al.
patent: 5434135 (1995-07-01), Parikh et al.
patent: 5705485 (1998-01-01), Cini et al.
patent: 5885956 (1999-03-01), Nardi et al.
patent: 6242666 (2001-06-01), Sarvetnick et al.
patent: 6271436 (2001-08-01), Piedrahita et al.
patent: 6288301 (2001-09-01), Nardi et al.
patent: WO 93/03757 (1993-03-01), None
patent: WO 00/29438 (2000-05-01), None
Simpson et al., “Rat epidermal growth factor: complete amino acid sequence”, Eur. J. Biochem., 153:629-637 (1985).
Database GenCore on EST, ID I52995, SAGGI, S.J., et al., “Epidermal Growth Factor Precursor-Rat”, Gene Sequence, Jun. 1999.
Database GenCore on EST, ID AAP61038, Fujisawa Pharm KK, “Urogastron Precursor for Chemical Synthesis”, Gene Sequence, Jul. 1991.
International Search Report for International Application No. PCT/US02/33907, mailed Jul. 29, 2003.
“The Isolation of the Urogstrones—Inhibitors of Gastric Acid Secretion—from Human Urine”, Hoppe-Seyler's Z. Physiol. Chem., Bd.356, pp. 1765-1774, Nov. 1975.
Carpenter et al., “Human Epidermal Growth Factor and the Proliferation of Human Fibroblasts”, J. Cell. Physiol., vol. 88, pp. 227-238, 1976.
Hollenberg et al., “Epidermal Growth Factor-Urogastone: Biological Activity and Receptor Binding of Derivatives”, Molecular Pharmacology, vol. 17, pp. 314-320, Jan. 10, 1980.
Koch et al., “Molecular Species of Epidermal Growth Factor Carrying Immunosuppressive Activity”, Journal of Cellular Biochemistry, vol. 25, pp. 45-59, 1984.
DiAugustine et al., “Evidence for Isoaspartyl (Deamidated) Forms of Mouse Epidemal Growth Factor”, Analytical Biochemistry, vol. 165, pp. 420-429, 1987.
George-Nascimento et al., “Characterization of Recombinant Human Epidermal Growth Factor Produced in Yeast”, Biochemistry, vol. 27, pp. 797-802, 1988.
Gregory et al., “The Contribution of the C-terminal Undecapeptide Sequence of Urogastone-Epidermal Growth Fator to its Biological Action”, Regulatory Peptides, vol. 22, pp. 217-226, 1988.
Burgess et al., “Murine Epidermal Growth Factor: Structure and Function”, Biochemistry, vol. 27, pp. 4977-4985, 1988.
Araki et al., “Stability of Recombinant Epidermal Growth Factor in Various Solutions”, Chem. Pharm. Bull., vol. 37, No. 2, pp. 404-406, 1989.
George-Nascimento et al., “Replacement of a Labile Aspartyl Residue Increases the Stability of Human Epidermal Growth Factor”, Biochemistry, vol. 29, pp. 9584-9591, 1990.
Clare et al., “Production of Mouse Growth Factor in Yeast: High-Level Secretion UsingPichia pastorisStrains Containing Multiple Gene Copies”, vol. 105, pp. 205-212, Jun. 18, 1991.
Kuo et al., “Pharmacokinetic Evaluation of Two Human Epidermal Growth Factors (hEGF51 and hEGF53) in Rats”, Drug Metabolism and Description, vol. 20, No. 1, pp. 23-30, Oct. 7, 1991.
Karnes, Jr., William E., “Epidermal Growth Factor and Transforming Growth Factor-α”, Galanin: Biochemistry and Physiology, pp. 553-586, 1994.
Shin et al., “Synthesis and Biological Activity of N-Terminal-Truncated Derivatives of Human Epidermal Growth Factor (h-EGF)”, Peptides, vol. 16, No. 2, pp. 205-210, 1995.
Playford et al., “Epidermal Growth Factor is Digested to Smaller, Less Active Forms in Acidic Gastric Juice”, Gastroenterology, vol. 108, pp. 92-101, 1995.
Sizemore et al., “Impact of Receptor Downregualtion on Clearance of Two Human EGFs With Different Receptor Binding Activity”, Peptides, vol. 17, NO. 7, pp. 1229-1236, 1996.
Goodlad et al., “Comparison of the Mitogenic Activity of Human Epidermal Growth Factor I-53 and Epidermal Growth Factor I-48 in vitro and in vivo”, vol. 91, pp. 503-507, Jun. 25, 1996.
Gasslander et al., “Trophic Effects by Epidermal Growth Factor on Duodenal Mucosa and Exocrine Pancreas in Rats”, Eur Surg Res, vol. 29, pp. 142-149, 1997.
Calnan et al. Potency and Stabiliy of C Terminal Truncated Human Epidermal Grwoth Factor, Gat, vol. 47, pp. 622-627, Jun. 1, 2000.
Brand Stephen J.
Jones Susan D.
Magil Sheila G.
Pace Gary W.
Elrifi, Esq. Ivor R.
Johnson, Esq. David E.
Ketter James
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Vogel Nancy
LandOfFree
Epidermal growth factor protein and gene, and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epidermal growth factor protein and gene, and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epidermal growth factor protein and gene, and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559941